drugset / Trial / NCT01035164

Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers

NCT01035164 ↗

Phase 1 Completed 25 enrolled Bayer
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

PET (positron emission tomography) imaging with BAY85-8101 (ZK 6032924) in patients with Alzheimer's Disease compared to healthy volunteers.

Timeline

Start
2007-06
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject F-18 FEDAA1106 Diagnostic / imaging agent 185 mbq Intravenous
Subject F-18 FEDAA1106 Diagnostic / imaging agent 250 mbq Intravenous

Indications